| Literature DB >> 27847829 |
José González-Serrano1, Julia Serrano1, Rosa María López-Pintor1, Víctor Manuel Paredes1, Elisabeth Casañas1, Gonzalo Hernández1.
Abstract
Chronic hyperglycemia is associated with impaired wound healing and higher susceptibility to infections. It is unclear whether patients with diabetes mellitus (DM) present more oral mucosal disorders compared to control groups. The objectives were to compare (a) the prevalence rates of oral mucosal disorders in the DM and non-DM population and (b) the prevalence rates of specific disorders in the DM and non-DM population. Full-text articles were included if they met the following inclusion criteria: (a) they must be original articles from scientific journals, (b) they must be only cross-sectional studies in English, (c) the prevalence of oral mucosal disorders in DM patients must be evaluated, (d) results must be compared with a healthy control group, and (e) oral mucosal disorders must be specified in DM and non-DM group. All studies showed higher prevalence of oral mucosal disorders in DM patients in relation to non-DM population: 45-88% in type 2 DM patients compared to 38.3-45% in non-DM groups and 44.7% in type 1 DM patients compared to 25% in non-DM population. Tongue alterations and denture stomatitis were the most frequent significant disorders observed. The quality assessment following the Joanna Briggs Institute (JBI) Prevalence Critical Appraisal Tool showed the low quality of the existing studies.Entities:
Mesh:
Year: 2016 PMID: 27847829 PMCID: PMC5099460 DOI: 10.1155/2016/5048967
Source DB: PubMed Journal: J Diabetes Res Impact factor: 4.011
Figure 1Flow diagram of the literature search, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). PubMed/MEDLINE, Scopus, and ScienceDirect: (diabetes OR “diabetes mellitus”) AND (“oral mucosal lesions” OR “oral diseases” OR “oral pathology”) AND (prevalence OR diagnosis); Cochrane Library: (diabetes OR (diabetes mellitus)) AND ((oral mucosal lesions) OR (oral diseases) OR (oral pathology)) AND (prevalence OR diagnosis).
General characteristics of selected studies.
| Guggenheimer et al., 2000 [ | Saini et al., 2010 [ | Bastos et al., 2011 [ | Mohsin et al., 2014 [ | |||||
|---|---|---|---|---|---|---|---|---|
| Type of study | Cross-sectional | Cross-sectional | Cross-sectional | Cross-sectional | ||||
|
| ||||||||
| Country | USA | Malaysia | Brazil | Pakistan | ||||
|
| ||||||||
| Patients recruited at | Department of Oral Medicine, University of Pittsburgh | Endocrinology Clinic of Medical Hospital and Department of Dental School | Clinic of Periodontics, Estadual Paulista University | Baqai Institute of Diabetology and Endocrinology | ||||
|
| ||||||||
| Sample | 673 | 840 | 257 | 800 | ||||
| Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls | |
|
| ||||||||
| Age (years) | 32.5 ± 0.3 | Cases | Controls | Cases | Controls | Male 51 ± 8.85 | ||
| Cases | Controls | Cases | Controls | |||||
|
| ||||||||
| Gender | Male, 312 | Male, 352 | Male, 109 | Male, 482 | ||||
| Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls | |
|
| ||||||||
| Type of DM | T1DM | T1DM, 29 | T2DM | T2DM | ||||
|
| ||||||||
| Period of time with DM | U | 8,36 ± 6.08 years: | <10 years: 36 (24.7%) | U | ||||
|
| ||||||||
| Treatment for DM | Insulin 405 | Oral hypoglycemics, 274 | Oral hypoglycemics, 98 (67.1%) | U | ||||
|
| ||||||||
| Oral mucosal disorders diagnosis criteria | Based on onset, duration, oral habits, clinical appearance, history of trauma, and previous episodes | Based on WHO guide to epidemiology and diagnosis of oral mucosal diseases | U | U | ||||
|
| ||||||||
| Biopsy when needed | U | Yes | Yes | Yes | ||||
|
| ||||||||
| Clinical examination method | Examination light | Electrical overhead light | Artificial light | Visible light | ||||
|
| ||||||||
| Clinician and experience | 2 oral medicine specialists with 10 years of experience | Single examiner assessed by an oral medicine specialist with more than 7 years of experience | Stomatologist | U | ||||
U: unspecified.
Confounding factors of selected studies.
| Guggenheimer et al., 2000 [ | Saini et al., 2010 [ | Bastos et al., 2011 [ | Mohsin et al., 2014 [ | |||||
|---|---|---|---|---|---|---|---|---|
| Tobacco | Cases | Controls | Excluded | Cases | Controls | U | ||
|
| ||||||||
| Other drugs taken | Cases | Controls | Cases | Controls | 39.2% taking a daily medication, of which 73.3% were antihypertensives and 56% were antidepressants | U | ||
|
| ||||||||
| Dentures users | Cases | Controls | U | U | U | |||
|
| ||||||||
| DM diagnosis | U | U | Controls: excluded by fasting blood glucose level | U | U | Controls: excluded by fasting blood glucose level | ||
|
| ||||||||
| Glycosylated hemoglobin (HbA1c) | 11 ± 0.1 | 8,49 ± 2,25 | Adequate (<7): 38 (26%) | U | ||||
|
| ||||||||
| Diabetic complications | Nephropathy, 23.2% | 14.5% | 65 (44.5%) | Excluded | ||||
U: unspecified.
JBI Critical Appraisal Checklist for studies reporting prevalence data.
| Guggenheimer et al., 2000 [ | Saini et al., 2010 [ | Bastos et al., 2011 [ | Mohsin et al., 2014 [ | |
|---|---|---|---|---|
| (1) Was the sample representative of the target population? | Y | Y | Y | U |
| (2) Were study participants recruited in an appropriate way? | U | U | U | U |
| (3) Was the sample size adequate? | U | Y | U | Y |
| (4) Were the study subjects and setting described in detail? | U | U | U | U |
| (5) Is the data analysis conducted with sufficient coverage of the identified sample? | U | U | U | U |
| (6) Were objective, standard criteria used for measurement of the condition? | U | U | N | N |
| (7) Was the condition measured reliably? | U | U | U | U |
| (8) Was there appropriate statistical analysis? | Y | Y | Y | Y |
| (9) Are all the important confounding factors/subgroups/differences identified and accounted for? | N | N | N | N |
| (10) Were subpopulation identified using objective criteria? | U | Y | Y | U |
| Total number of “Y” | 2 | 4 | 3 | 2 |
| Quality assessment | low | low | low | low |
Y: yes; N: no; U: unclear; N/A: not applicable.
Distribution of oral mucosal disorders in DM patients and controls.
| Guggenheimer et al., 2000 [ | Saini et al., 2010 [ | Bastos et al., 2011 [ | Mohsin et al., 2014 [ | |||||
|---|---|---|---|---|---|---|---|---|
| Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls | |
|
|
|
|
|
|
|
|
| |
| Subjects with one or more oral disorders | 180 (44.4) | 67 (25) | 189 (45) | 161 (38.3) | 129 (88) | 50 (45) | 225 (60.8) | 145 (39.2) |
| Angular cheilitis | 13 (3.2) | 3 (1.1) | 10 (2.4) | 3 (0.7) | 22 (15) | 10 (9) | ||
| Aphthous stomatitis | 6 (1.5) | 8 (3.0) | 5 (1.2) | 3 (0.7) | ||||
| Atrophy of tongue papillae | 36 (8.9) | 6 (2.2) | 4 (2.7) | 0 (0) | ||||
| Pseudomembranous candidiasis | 2 (0.5) | 1 (0.4) | ||||||
| Denture stomatitis | 19 (4.7) | 4 (1.5) | 45 (10.7) | 26 (6.2) | ||||
| Epulis fissuratum | 3 (0.7) | 0 (0.0) | ||||||
| Fissured tongue | 22 (5.4) | 1 (0.4) | 114 (27.1) | 112 (26.7) | 26 (17,8) | 4 (3.6) | 63 (15.9) | 40 (9.9) |
| Fistulous tract | 4 (1.0) | 1 (0.4) | ||||||
| Gingival hyperplasia | 7 (1.7) | 4 (1.15) | ||||||
| Herpes labialis | 1 (0.2) | 2 (0.7) | ||||||
| Inflammatory papillary hyperplasia | 3 (0.7) | 0 (0.0) | ||||||
| Fibroma | 10 (2.5) | 1 (0.4) | 5 (1.2) | 5 (1.2) | ||||
| Lichen planus | 2 (0.5) | 2 (0.7) | 2 (0.5) | 0 (0) | 9 (6.1) | 0 (0) | 7 (1.8) | 4 (1) |
| Median rhomboid glossitis | 29 (7.2) | 1 (0.4) | 4 (1) | 5 (1.2) | ||||
| Geographic tongue | 22 (5.4) | 9 (3.4) | 17 (4) | 4 (1) | 8 (5,4) | 1 (0,9) | 5 (1.3) | 4 (1) |
| Papilloma | 1 (0.2) | 1 (0.4) | ||||||
| Traumatic ulcer | 14 (3.5) | 3 (1.1) | 8 (1.9) | 2 (0.5) | ||||
| Frictional keratosis | 10 (2.4) | 14 (3.3) | ||||||
| Coated tongue | 42 (28,7) | 9 (8.1) | 106 (26.8) | 32 (7.9) | ||||
| Varices | 30 (20,5) | 6 (5.4) | ||||||
| Melanin pigmentation | 12 (8,2) | 2 (1,8) | 60 (15.2) | 45 (11.1) | ||||
| Leukoedema | 8 (5.4) | 2 (1.8) | ||||||
| Actinic cheilitis | 37 (25.3) | 6 (5.4) | ||||||
| Leukoplakia | 6 (2.7) | 1 (1.8) | 14 (3.5) | 12 (3) | ||||
| Nicotinic stomatitis | 3 (2) | 2 (1.8) | ||||||
| Oral submucous fibrosis | 8 (2) | 12 (3) | ||||||
| Linea alba | 31 (7.1) | 12 (3) | ||||||
| Fordyce granules | 9 (2.3) | 0 (0) | ||||||